Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

This setup has several features that lower the chance of a clearly positive Phase 2 readout. The study is open-label and split into two materially different cohorts: locoregionally advanced disease using PFS after RP3 plus chemoradiation then nivolumab, and recurrent/metastatic disease using ORR with chemotherapy plus nivolumab. That creates endpoint heterogeneity and makes the overall efficacy story harder to win cleanly. SCCHN is a difficult, high-risk population, and the regimen is complex, combining an oncolytic biologic with intensive backbone therapy, which raises execution, enrollment, tolerability, and attribution risk. The strongest negative signal is the trial status: Withdrawn, despite a primary completion date that should already have been reached. Withdrawal materially reduces the chance of a mature, interpretable dataset and increases the odds of no meaningful efficacy disclosure or a strategically unfavorable halt. ORR in the R/M cohort is somewhat achievable, but the full package needed for a clearly positive result looks unlikely.

The trial (NCT05743270) has a current status of 'Withdrawn,' which is the most critical fact. A withdrawn trial means it was stopped before enrolling any participants—no patients were treated, no data were collected, and therefore no efficacy results (positive or negative) can be reported. The question asks whether results will be positive, but there are no results to evaluate. The estimated primary completion date was March 2026, already past, and the trial was withdrawn rather than completed. Replimune's RP3 oncolytic immunotherapy program in SCCHN combined with nivolumab and chemo/CCRT was a reasonable Phase 2 design with dual cohorts (LA and R/M), using PFS and ORR as endpoints. However, none of this matters because the study never generated data. Withdrawn trials essentially cannot produce positive results. The only scenario for YES would be if 'withdrawn' were a data error and results were actually reported, which is extremely unlikely given the registry status. I assign ~3% probability to account for a minuscule chance of misclassification.

The trial status is critical: it shows 'Withdrawn' with the primary completion date already passed by 32 days. This indicates the Phase 2 study of RP3 combined with nivolumab and chemoradiation for SCCHN was terminated before achieving its primary endpoints. Withdrawn trials typically signal negative outcomes, safety concerns, or strategic discontinuation rather than success. Given this status, the probability of positive results is very low. The trial had two cohorts (LA with PFS endpoint, R/M with ORR endpoint), but without completion, there are no results to evaluate. The market price of ~50% appears to ignore the withdrawn status, likely pricing in uncertainty about what 'withdrawn' specifically means for the binary question.

The trial's status is 'Withdrawn', meaning the study has been terminated before completion. The primary completion date has already passed, and no results are available. A withdrawn trial, by definition, does not produce a positive or negative result for its endpoints; it yields no interpretable efficacy data. Therefore, the intrinsic probability of a positive result is effectively zero. The trial design involved RP3, an oncolytic virus, combined with standard therapies in SCCHN. While the combination was mechanistically rational, the withdrawal—likely due to strategic portfolio decisions, safety, or lack of efficacy signals—precludes any chance of a positive outcome from this specific study.

The trial (NCT05743270) is explicitly listed as 'Withdrawn,' signifying termination prior to primary completion, with no endpoint data generated. This operational failure precludes any possibility of positive results. The design includes two cohorts: Locoregionally Advanced (LA) assessing PFS (time to progression or death up to 3 years), prone to radiological assessment bias, and Recurrent/Metastatic (R/M) using ORR (CR+PR), a more objective but stringent measure in pretreated patients. Patient population comprises inoperable advanced SCCHN (oral cavity, oropharynx, etc.), with dismal prognosis and limited responses to standards like CCRT or chemo+nivolumab. RP3, Replimune's oncolytic virus, builds on RP1's prior immuno-oncology signals, but combo execution risks were high. Primary completion overdue by 32 days underscores sponsor challenges. No data disclosure expected, eliminating positive resolution risk. Intrinsic YES probability is definitively 0%.

The trial's current status is explicitly listed as 'Withdrawn' with a primary completion date approximately one month in the past. A withdrawn status indicates the study was halted before completing its intended objectives, meaning no statistically valid primary endpoint data will be generated to support a 'positive' result. Without study completion and analysis, the formal criteria for a positive outcome cannot be met. While the design involving RP3, nivolumab, and CCRT in SCCHN was mechanistically sound, and the dual-cohort structure (LA and R/M) was appropriate, operational failure negates scientific merit. The question asks if results will be positive; a withdrawn trial produces no positive results. Thus, the probability of a positive resolution is near zero, limited only by semantic ambiguity regarding the release of partial data.

The trial status is 'Withdrawn' with primary completion date 32 days past due. This indicates early termination, likely due to futility, safety concerns, or strategic withdrawal. Withdrawn trials rarely produce positive results. The Phase 2 design with two distinct cohorts (locoregionally advanced and recurrent/metastatic) using different endpoints (PFS vs ORR) adds complexity but doesn't overcome the withdrawal signal. RP3 is an oncolytic virus in combination with chemoradiation and nivolumab—a crowded space where many agents fail. No interim data has been disclosed suggesting efficacy. The sponsor (Replimune) has not communicated positive signals. Disclosure risk of negative data is moderate given the withdrawal status already public. Overall, probability of positive results is low.

The trial NCT05743270 is officially registered as 'Withdrawn' on ClinicalTrials.gov. By definition, a withdrawn status means the study was halted prematurely before enrolling its first participant. Without any enrolled patients, no clinical data will be generated, and therefore the trial cannot possibly report positive results for its primary endpoints (Progression-Free Survival for the LA Cohort and Objective Response Rate for the R/M Cohort). Prediction market rules consistently resolve withdrawn trials without efficacy data as NO, as the criteria for a positive statistical and clinical outcome cannot be met. Since there will be no results, the intrinsic probability of reporting positive results is strictly 0%. The sponsor, Replimune, may have discontinued this specific combination strategy or trial design before initiation for strategic, financial, or portfolio prioritization reasons. Regardless of the underlying rationale for the withdrawal, the objective fact remains that no trial took place and no outcomes will be reported. This represents a definitive and absolute failure to produce positive results, locking the intrinsic probability at zero.

The trial is currently listed as withdrawn, which significantly reduces the likelihood of positive results. The study was evaluating RP3 in combination with other therapies for advanced squamous cell carcinomas of the head and neck. Withdrawal often indicates issues with patient recruitment, funding, or trial execution, all of which negatively impact the chances of obtaining positive results.